Search

everythinglearnresearchcommunity

for

Search:↓

The user's 42 month experience using finasteride for hair loss, their opinion on minoxidil use and the potential of pyrilutamide and another Chinese drug as treatments.

The user is experiencing hair loss with possible causes including chronic telogen effluvium, diffuse alopecia areata, and androgenic alopecia. They have tried treatments like Nizoral shampoo, minoxidil, and finasteride, and are considering a biopsy for further clarity.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

Male pattern baldness (MPB) may be an early warning sign for type 2 diabetes due to its association with insulin resistance. Treatments discussed include testosterone therapy and finasteride, which affects hormone levels related to hair loss and insulin sensitivity.

The user has been using finasteride, dutasteride, and minoxidil without success and is considering a comprehensive blood test to explore other causes of hair loss. They are unsure about the necessity and cost of the extensive tests and are seeking advice on whether to proceed with the full panel or focus on specific tests.

The conversation discusses the ineffectiveness of dutasteride in halting hair loss for the user and explores the potential of PP405, which works through a different mechanism. Suggestions include considering a biopsy to determine the cause of hair loss and exploring other treatments like RU58841.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

A user on finasteride, minoxidil, dermastamp, and Nizoral is seeing baby hairs and asks if it's regrowth. Another user confirms it is regrowth and encourages them to continue.

A natural compound called C3A from Aronia Chokeberry can help prevent hair loss by counteracting the effects of DHT. The user has been taking 50 grams of dried organic Aronia Chokeberry daily for 30 days and will update with photos in 60 days.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.

Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.

A user shared their positive experience with a hair transplant at Eugenix in India, noting the professionalism and natural results. They mentioned using 2815 grafts and discussed the clinic's controversial name, but did not mention using specific treatments like Minoxidil or finasteride.

The user shared their hormone levels over time while using finasteride and dutasteride for hair loss. They experienced a significant drop in DHT levels but continued to lose hair, hoping for better results in the future.

A mixture of MSM, kombucha, and black tea was applied topically for hair growth in mice. The conversation suggests skepticism about translating these results to humans.

L'Oreal is working on hair cloning, with multiple companies using similar techniques, making hair cloning likely by 2030. The conversation expresses optimism about the progress and potential affordability of hair cloning solutions.

Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.

Hair loss treatments like GT20029, pyrilutamide, and Follica show promise in 2022. Phase 1 and 2 trials are underway, and new hair growth studies have been published.

Pelage received $120 million for phase 3 of PP405, a potential hair loss treatment, but there is skepticism about its success. Some users believe any improvement over finasteride is a win, while others expect full hair regrowth.

Users discuss using pyrilutamide for hair loss, seeking alternatives to 5AR inhibitors. They mention using minoxidil, ketoconazole shampoo, and RU58841.

HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.

Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.

A user claimed significant hair regrowth over 18 months using minoxidil, finasteride, ketoconazole shampoo, dermastamping, and supplements without a transplant. Commenters were skeptical, suspecting a hair system might be involved.

The conversation is about someone experiencing significant hair regrowth after 23 days on Finasteride and Biotin, with others suggesting additional treatments like Minoxidil and microneedling. Some doubt the speed of hair growth, while others believe Biotin isn't contributing to the results.

Hair loss treatments, including finasteride and RU58841, with humorous speculation about the cause of death for an ancient mummy that still had hair.

GeneTherica is discussed as a source for RU58841, with ordering possible via WhatsApp. The conversation focuses on the legitimacy of this supplier for hair loss treatment.

New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.

Hair transplant recipients are concerned about whether dormant follicles are permanently damaged by incisions, but some believe undamaged follicles could still regrow if a treatment like PP405 is effective. Opinions vary on the impact of transplants on original follicles, with some suggesting treatments like finasteride can help regrow hair.

The user successfully regrew hair using Finasteride, Minoxidil, and microneedling, achieving thicker hair and a fuller hairline. They recommend this method over hair transplants, highlighting the importance of patience and consistency.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.